Blocking antibodies for this pathway, such as anti-CTLA-4 or anti-PD-1 mAb, lead to remarkable outcome in advanced stages of diseases and achieve response rates of up to 30% in metastatic melanoma patients that have failed standard treatments.2,3. This evidence concerns the gene CTLA4 and metastatic melanoma.